Skip to content

Basket

You currently have no items in your basket.

Total (excl. vat) £0.00
View basket & checkout
Proteins and Peptides

Human B-Cell Activating Factor (BAFF), Active Protein

Product Sizes
50 ug
£606.00
RPU56271-50UG
100 ug
£749.00
RPU56271-100UG
1 mg
£3385.00
RPU56271-1MG
About this Product
SKU:
RPU56271
Additional Names:
B lymphocyte stimulator|BLYS|CD257|Dendritic cell-derived TNF-like|TALL1|THANK|TNFSF13B|TNFSF20|Tumor Necrosis Factor Ligand Superfamily Member 13B|ZTNF4
Application:
Detection/Quantitation, Tissue Culture
Buffer:
Freeze-dried powder|PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
CE/IVD:
RUO
Extra Details:
Human B-Cell Activating Factor (BAFF), Active Protein is a purified Prokaryotic Protein.
Formulation:
Freeze-dried powder
Immunogen:
B-Cell Activating Factor (BAFF)
Molecular Weight:
22kDa
Physical State:
freeze-dried
Purity:
>90%
Shipping Conditions:
Blue Ice
Storage Conditions:
-20[o]C Avoid freeze/thaw cycles.
Supplier:
Biomatik
Type:
Proteins, Peptides, Small Molecules & Other Biomolecules: Recombinant Proteins
Catalog Protein.JPG
Figure . SDS-PAGE
Figure . Western Blot
Figure. The binding activity of TNFSF13B with ITGb1.Tumor necrosis factor ligand superfamily member 13B protein (TNFSF13B) also known as B-cell activating factor (BAFF) is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This cytokine is a ligand for receptors TNFRSF13B/TACI, TNFRSF17/BCMA, and TNFRSF13C/BAFF-R. This cytokine is expressed in B cell lineage cells, and acts as a potent B cell activator. It has been also shown to play an important role in the proliferation and differentiation of B cells. Besides, Integrin Beta 1 (ITGb1) has been identified as an interactor of TNFSF13B, thus a binding ELISA assay was conducted to detect the interaction of recombinant human TNFSF13B and recombinant human ITGb1. Briefly, TNFSF13B were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100uL were then transferred to ITGb1-coated microtiter wells and incubated for 2h at 37°C. Wells were washed with PBST and incubated for 1h with anti-TNFSF13B pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37°C. Finally, add 50uL stop solution to the wells and read at 450nm immediately. The binding activity of TNFSF13B and ITGb1 was shown in Figure 1, and this effect was in a dose dependent manner.